<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="62604">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02290925</url>
  </required_header>
  <id_info>
    <org_study_id>RAJ-001</org_study_id>
    <nct_id>NCT02290925</nct_id>
  </id_info>
  <brief_title>The Effect of Biscuit Containing Kothala Himbutu on Blood Glucose Levels in Patients With Diabetes</brief_title>
  <official_title>The Effect of a Biscuit Containing the Extract of Salacia Reticulata on Glycaemia in Patients With Type II Diabetes Mellitus A Two Center Randomized Double Blind Placebo Controlled Two Period Two Sequence Crossover Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rajarata University, Sri Lanka</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Peradeniya</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rajarata University, Sri Lanka</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators intend to conduct a double blind randomized clinical trial to investigate
      the effect of a biscuit containing herbal extract, available in the market on the fasting
      blood sugar control in patients with diabetes mellitus and also to find out whether there
      are any side effects on other vital organs such as kidneys and liver.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The effect of a biscuit containing the extract of Salacia reticulata (Kothala Himbutu) on
      the reduction of blood glucose levels in patients with Type II Diabetes Mellitus. A two
      center randomized double blind placebo controlled two period two sequence crossover clinical
      trial.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in glycosylated haemoglobin (non-inferiority)</measure>
    <time_frame>before (0), after 3 months and after 7 months (there is one month wash over period as this is a cross over trial) Zero time period means just before starting the active ingredient or placebo</time_frame>
    <description>As this is the cross over trial and patients normal medications will be changed by the clinician to control glycaemia we will be looking into major deterioration of the glycaemic control of the patients who are on biscuits containing active ingredient</description>
  </primary_outcome>
  <primary_outcome>
    <measure>serious adverse effects</measure>
    <time_frame>during the period patient is taking biscuit conatining an extract of Salacia reticulate, which is three months</time_frame>
    <description>patients will be on biscuit congaing the active ingredient for three months only</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Six point blood sugar series</measure>
    <time_frame>one day during the 7 months patients are in the trial including wash out period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">195</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Kothala Himbutu biscuit</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A biscuit containing Kothala Himbutu (Salacia reticulata) extract. This biscuit is available in the supermarkets. Four biscuits twice a day for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo biscuit</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>An identical biscuit without the herbal extract from Kothala Himbutu (Salacia reticulate)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kothala Himbutu Biscuit</intervention_name>
    <description>Kothala Himbutu biscuit (Salacia reticulata). This herb has been used by traditional physicians to control blood sugar.</description>
    <arm_group_label>Kothala Himbutu biscuit</arm_group_label>
    <other_name>Salacia reticulata</other_name>
    <other_name>Munchee Kothala Himbutu biscuit</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo Biscuit</intervention_name>
    <description>Placebo biscuit without the herbal extract of Kothala Himbutu (Salacia reticulate)</description>
    <arm_group_label>placebo biscuit</arm_group_label>
    <other_name>Biscuit</other_name>
    <other_name>Munchee biscuit</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Onset of diabetes mellitus after the age of 30 years

          2. Aged between 30 and 65 years

          3. Stable glycaemic control over the preceding 2-3 months. They will be initially
             selected from a range of HBA1C varying from 6.5 - 14 and the individual subject
             should not have a variation of &gt;20% between the previous HBA1C and the HBA1C done at
             the commencement of the study

        Exclusion Criteria:

          1. Having severe disabling long-term complications of diabetes mellitus such as severe
             retinopathy, neuropathy and nephropathy.

             1.1 Patients with advanced diabetic eye disease. 1.2. Severe Neuropathy (to be
             assessed by clinician). 1.3. Chronic kidney disease with estimated Glomerular
             filtration rate less than 30ml/hour

          2. Severe valvular heart disease.

          3. Currently or previously treated for any malignancy

          4. Already on treatment with Kothala himbutu

          5. Pregnant or lactating females

          6. Patients on steroid treatment

          7. Patients on steroid treatmentThose on Insulin therapy

          8. Severe liver disease (AST &gt; 5 X times the upper limit)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suneth B Agampodi, MBBS, MD</last_name>
    <role>Study Director</role>
    <affiliation>Faculty of Medicine &amp; Allied Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Teaching Hospital Perdeniya</name>
      <address>
        <city>Peradeniya</city>
        <state>Central</state>
        <zip>20400</zip>
        <country>Sri Lanka</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teaching Hospital Anuradhapura</name>
      <address>
        <city>Anuradhapura</city>
        <state>North Central Province</state>
        <zip>50000</zip>
        <country>Sri Lanka</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sri Lanka</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 3, 2016</lastchanged_date>
  <firstreceived_date>November 7, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>biscuit containing Salacia reticulate</keyword>
  <keyword>randomised controlled trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
